However, in SCD cells, TGFβ treatment led to a significant increase in glucose (i.e. a decrease in glucose utilization, p = 0.00049, which was wholly abrogated by VPA [p = 9.9e-4, interaction term; Figure 2F]). Here, TGFB1 is linked to Schnyder corneal dystrophy.